Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
SpaceX Turbine Push Unlikely to Threaten Howmet, Bernstein Says 
Anthropic IPO Marketing Expected to Start in Mid-October 
SEC Seeks ISS Client Voting Records in Proxy Adviser Probe 
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
OpenAI Launches GPT-6 Astra With Advanced AI Agent Capabilities 
Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 
South Korea, US Discuss Chip Investments Amid Tariff Plans 
Nvidia Eyes $2.5 Billion Investment in Thinking Machines Lab 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
Xiaomi Shares Jump on Europe EV Expansion Plan 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
Add as a preferred source on Google
SK Biopharmaceutical is eyeing a share of the 4 trillion won US antiepileptic drug market with its cenobamate tablet Xcopri, which treats partial-onset seizures in adults.
The drug, approved by the US Food and Drug Administration (FDA) on November 21 last year, provides an extra needed treatment option for people with seizures.
Xcopri is the first Korean novel drug, researched and developed entirely and independently by a Korean pharma firm, notes SK Biopharmaceutical CEO Cho.
It is a product of Cho's 15-year research and development drive.
According to the US FDA, the safety and efficacy of XCOPRI were established in two studies that enrolled 655 adults, which were randomized, double-blind, and placebo-controlled.
The FDA granted Xcopri's approval to SK Life Science Inc., the US arm of SK Biopharmaceutical.
Thus, SK Life Science will undertake the US distribution of Xcopri.
